PMID- 32367073
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20240210
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 123
IP  - 2
DP  - 2020 Jul
TI  - Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of 
      gastric cancer in two population-based studies.
PG  - 307-315
LID - 10.1038/s41416-020-0860-4 [doi]
AB  - BACKGROUND: Studies have shown increased gastric cancer risk in users of proton 
      pump inhibitors (PPI) and histamine-2 receptor antagonists, questioning the 
      safety of gastric acid suppression. Therefore, we conducted a case-control study 
      within the Scottish Primary Care Clinical Informatics Unit (PCCIU) database and a 
      cohort study in the UK Biobank. METHODS: In PCCIU, five controls were matched to 
      cases diagnosed in 1999-2011, and medications were determined from GP records. 
      Odds ratios (OR) and 95% confidence intervals (CI) were calculated using 
      conditional logistic regression. In the UK Biobank, medications were 
      self-reported at cohort entry 2006-2010, and gastric cancer ascertained from 
      cancer registries until 2014. Hazard ratios (HR) were calculated using Cox 
      regression. RESULTS: PCCIU contained 1119 cases and 5394 controls. UK Biobank 
      contained 250 cases in 471,779 participants. PPI users had a higher gastric 
      cancer risk in PCCIU and UK Biobank when applying a 1-year lag (adjusted 
      OR = 1.49, 95% CI 1.24, 1.80; adjusted HR = 1.28, 95% CI 0.86, 1.90, 
      respectively), but these associations were attenuated when using a 2-year lag 
      (adjusted OR = 1.13, 95% CI 0.91, 1.40; adjusted HR = 1.15, 95% CI 0.73, 1.82, 
      respectively). CONCLUSIONS: Overall, we observed little consistent evidence of an 
      increased risk of gastric cancer with PPI use.
FAU - Liu, Peipei
AU  - Liu P
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK. 
      pliu03@qub.ac.uk.
FAU - McMenamin, Una C
AU  - McMenamin UC
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
FAU - Johnston, Brian T
AU  - Johnston BT
AD  - Belfast Health and Social Care Trust, Belfast, UK.
FAU - Murchie, Peter
AU  - Murchie P
AUID- ORCID: 0000-0001-9968-5991
AD  - Academic Primary Care, Institute of Applied Health Sciences, University of 
      Aberdeen, Aberdeen, UK.
FAU - Iversen, Lisa
AU  - Iversen L
AD  - Academic Primary Care, Institute of Applied Health Sciences, University of 
      Aberdeen, Aberdeen, UK.
FAU - Lee, Amanda J
AU  - Lee AJ
AD  - Medical Statistics Team, Institute of Applied Health Sciences, University of 
      Aberdeen, Aberdeen, UK.
FAU - Vissers, Pauline A J
AU  - Vissers PAJ
AD  - Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), 
      Utrecht, The Netherlands.
FAU - Cardwell, Chris R
AU  - Cardwell CR
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
LA  - eng
GR  - MC_PC_17228/MRC_/Medical Research Council/United Kingdom
GR  - MR/T019859/1/MRC_/Medical Research Council/United Kingdom
GR  - 20100/CRUK_/Cancer Research UK/United Kingdom
GR  - MC_QA137853/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - 820484N8I3 (Histamine)
SB  - IM
MH  - Aged
MH  - Case-Control Studies
MH  - Female
MH  - Histamine/metabolism
MH  - Histamine H2 Antagonists/*administration & dosage/adverse effects
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Proton Pump Inhibitors/*administration & dosage/adverse effects
MH  - Risk Factors
MH  - Stomach Neoplasms/*drug therapy/pathology
PMC - PMC7374738
COIS- The authors declare no competing interests.
EDAT- 2020/05/06 06:00
MHDA- 2021/02/20 06:00
PMCR- 2021/05/05
CRDT- 2020/05/06 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/03/27 00:00 [revised]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2021/05/05 00:00 [pmc-release]
AID - 10.1038/s41416-020-0860-4 [pii]
AID - 860 [pii]
AID - 10.1038/s41416-020-0860-4 [doi]
PST - ppublish
SO  - Br J Cancer. 2020 Jul;123(2):307-315. doi: 10.1038/s41416-020-0860-4. Epub 2020 
      May 5.